Patent · US Active

Anti-La antibodies and their use for immunotargeting

US10246516B2 · kind B2 · utility

0Cited by
4References
7Claims
0Family size

Assignee

Inventor

Key dates

Filing dateNov 18, 2016
Grant dateApr 2, 2019
Priority date
Expiry dateJun 22, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/73
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The invention relates to antibodies against the human La protein and to their use in immunotargeting, in particular the immunotargeting of tumor cells. The object of the invention is to provide improved antibodies which bind universal target structures on the surface of tumor cells, and to provide novel anti-La antibodies, in particular with a high affinity for La, a universal target structure on tumor cells, which make it possible to use the antibodies as recombinant fragments for immunotargeting. The invention comprises recombinant antibodies comprising: (i) a binding unit of an antibody which specifically binds to an epitope of a human nuclear antigen, preferably human La protein, and (ii) a binding unit of an antibody which specifically binds to an effector cell or of a ligand which specifically binds to an effector cell. The invention furthermore comprises novel antibodies which specifically bind the human La protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.